HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: pr.108.00372v1 60/2/143    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Hay, D. L. Articles by Quirion, R. PubMed PubMed Citation Articles by Hay, D. L. Articles by Quirion, R.

IUPHAR Nomenclature Report

International Union of Pharmacology. LXIX. Status of the Calcitonin Gene-Related Peptide Subtype 2 Receptor

School of Biological Sciences, University of Auckland, Auckland, New Zealand (D.L.H.); School of Life and Health Sciences, Aston University, Birmingham, United Kingdom (D.R.P.); and Department of Psychiatry, Douglas Hospital Research Centre, McGill University, Montréal, Québec, Canada (R.Q.)

Abstract

I. Introduction

II. Studies on Cloned Receptors

A. Calcitonin Gene-Related Peptide and Adrenomedullin Receptors

B. Calcitonin and Amylin Receptors

III. Conclusions

Historically, calcitonin gene-related peptide (CGRP) receptors have been divided into two classes, CGRP₁ and CGRP₂. After the cloning of calcitonin receptor-like receptor (CLR) and receptor activity-modifying proteins (RAMPs), it became clear that the CGRP₁ receptor was a complex between CLR and RAMP1. It is now apparent that the CGRP₂ receptor phenotype is the result of CGRP acting at receptors for amylin and adrenomedullin. Accordingly, the term "CGRP₂" receptor should no longer be used, and the "CGRP₁" receptor should be known as the "CGRP" receptor.